# reload+after+2024-01-22 11:47:15.768851
address1§4149 Liberty Canyon Road
city§Agoura Hills
state§CA
zip§91301
country§United States
phone§805-730-0360
website§https://www.acelyrin.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody against insulin-like growth factor 1 receptor, which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease; and SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. The company was incorporated in 2020 and is headquartered in Agoura Hills, California.
fullTimeEmployees§108
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Shao-Lee  Lin M.D., Ph.D.', 'age': 56, 'title': 'Co-Founder, CEO & Director', 'yearBorn': 1967, 'fiscalYear': 2022, 'totalPay': 846246, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Melanie  Gloria B.S.N.', 'age': 45, 'title': 'Chief Operating Officer', 'yearBorn': 1978, 'fiscalYear': 2022, 'totalPay': 672581, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Gilbert M. Labrucherie J.D.', 'age': 51, 'title': 'Chief Financial Officer, Principal Financial Officer & principal accounting officer', 'yearBorn': 1972, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Mina  Kim', 'age': 49, 'title': 'Chief Legal & Administrative Officer', 'yearBorn': 1974, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Tyler  Marciniak', 'title': 'Head of Investor Relations & Communications', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Ron  Oyston', 'age': 53, 'title': 'Chief People Officer', 'yearBorn': 1970, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Paul M. Peloso M.D., M.Sc.', 'age': 65, 'title': 'Chief Medical Officer', 'yearBorn': 1958, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Suzy  Buckhalter CPA', 'title': 'Senior Director of Finance & Accounting', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Kenneth A. Lock', 'age': 49, 'title': 'Chief Commercial Officer', 'yearBorn': 1974, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Shephard  Mpofu M.D.', 'title': 'Senior Vice President of Development', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
currency§USD
dateShortInterest§1702598400
forwardEps§-4.2
exchange§NMS
quoteType§EQUITY
shortName§ACELYRIN, INC.
longName§Acelyrin, Inc.
firstTradeDateEpochUtc§1683207000
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§331b354b-7a4d-3b82-ac00-9819e1a01b9d
gmtOffSetMilliseconds§-18000000
targetHighPrice§68.0
targetLowPrice§8.0
targetMeanPrice§23.67
targetMedianPrice§12.5
recommendationMean§2.3
recommendationKey§buy
numberOfAnalystOpinions§6
quickRatio§11.821
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
